mg线上娱乐4371,mg线上娱乐平台网站

德国默天旎全自动制备平台技术助力博生吉mg线上娱乐平台网站CAR T项目提速

来源:博生吉mg线上娱乐平台网站      mg线上娱乐4371:2018-01-29    浏览量:8634

○博生吉mg线上娱乐平台网站和默天旎达成谅解备忘录,默天旎企业对博生吉mg线上娱乐平台网站在中国开展的嵌合抗原受体(CAR)T细胞生产、临床试验提供支撑与合作。


○默天旎的CliniMACS Prodigy®  和  MACSQuant ®  平台将会为博生吉mg线上娱乐平台网站提供全自动的 CAR T 细胞制造解决方案、相应的质量控制方案、快速分析方案以及相关的培训。


2018 年 1 月 29 日,中国合肥——博生吉mg线上娱乐平台网站与德国默天旎企业今天宣布双方达成合作谅解备忘录,在合肥建设基于 CliniMACS Prodigy  和  MACSQuant 平台的全自动 CAR T 细胞制备工厂。默天旎企业在细胞制备及其相关技术的全球领先地位,将会为博生吉mg线上娱乐平台网站企业的 CAR T 疗法提供强力支撑。该协议致力于在 CAR T 疗法的各个领域展开双方的深度合作,包括稳定的供应关系、共同开发定制化试剂、联合开展免疫治疗研发项目,包括新型慢病毒载体的开发等。


博生吉mg线上娱乐平台网站董事长兼首席实行官杨林博士表示:加强与默天旎的合作是十分令人振奋的消息,因为这将强化博生吉mg线上娱乐平台网站在全球建设较先进的全自动CAR T细胞制造平台的技术能力。凭借 CliniMACS Prodigy  和  MACSQuant 平台,以及来自默天旎的系统培训和支撑服务,这将满足博生吉mg线上娱乐平台网站积极推进 CAR T 细胞项目临床研究时间表的要求。


默天旎总经理 Boris Stoffel 博士表示:近三十年来,默天旎一直在为全世界的患者开发和提供细胞疗法解决方案。与博生吉mg线上娱乐平台网站的深度合作将加速新的细胞治疗技术的开发,让中国患者能够在不远的将来可以受益于新的细胞和基因治疗产品。


关于细胞和基因治疗


细胞和基因疗法通过对免疫细胞进行基因修饰来治疗肿瘤,是较具潜力的肿瘤治疗方向。它利用免疫系统的天然属性和肿瘤的分子遗传学信息,重新编程患者的免疫细胞,将其改造成为杀伤肿瘤的强大武器。


为了开展细胞和基因疗法的治疗,需要从患者的血液中取出免疫细胞进行修饰以产生所需的治疗效果。因此,要通过基因修饰来使患者免疫细胞获得特异性识别肿瘤、并且在患者体内可以长期发挥疗效的能力。将这些经过基因改造的免疫细胞回输到患者体内后,就可以对肿瘤细胞产生持久和有效的杀伤力。


博生吉mg线上娱乐平台网站细胞技术有限企业:由博生吉医药科技(苏州)有限企业与mg线上娱乐4371(股票代码:300009)共同投资组建而成。博生吉,PersonGen,Personalized Gene Therapy 的缩写,寓意着致力于个性化医药技术的研发与创新。博生吉致力于实现21世纪具有雄心的医学目标之一:攻克癌症,并立志成为肿瘤 CAR-T 和 CAR-NK 免疫细胞疗法的领导者。欲了解更多信息,请访问www.ankebio.com 或者 www.persongen.com 。


默天旎生物技术有限企业:默天旎企业在全球范围内提供促进生物医学研究和细胞治疗的产品和服务。默天旎的创新性工具服务于各个层面的研究:从基础到转化、再到临床应用。默天旎能为科学家和临床医生对细胞的制备、分析和应用的一整套产品组合。默天旎的技术平台涵盖了样品制备、细胞分离、细胞分选、流式细胞术、细胞培养和临床前成像等技术。更重要的是,默天旎有超过25年的专业常识背景,涉及免疫学、干细胞生物学、神经科学和癌症,以及血液学、移植工程和单采血液成分等临床研究领域。对于科学界,默天旎也提供全面的科学支撑,包括咨询和专家培训。如今,默天旎在全球 25 个国家拥有 2000 多名员工,致力于帮助世界各地的研究人员和临床医生,对科学和健康产生更强大的影响和贡献。现在,默天旎的产品已被用于超过 50000 个细胞治疗项目。欲了解更多信息,请访问www.miltenyibiotec.com 。


博生吉mg线上娱乐平台网站联系方式:

Shirley Zhang

+86 55165728067

Shirley.zhang@persongen.com

info@persongen.com


Miltenyi Biotec Media Contact

Svea Lübcke 

Marketing Communications 

Tel.: +49 2204 8306 6683

sveal@miltenyibiotec.de

press@miltenyibiotec.de 

Miltenyi Biotec’s automated manufacturing platform helps to accelerate PersonGen-Anke Therapeutics  CAR T cell program development


PersonGen-Anke and Miltenyi Biotec agree on a memorandum of understanding to support Chimeric Antigen Receptor (CAR) T cell manufacturing,clinical trials, and collaboration in China 。 


Miltenyi Biotec’s CliniMACS Prodigy® and MACSQuant® platforms will provide PersonGen-Anke with a fully automated CAR T cell manufacturing solution, matched quality control, express analysis, and training 。


Hefei,China, January 29, 2018 – PersonGen-Anke and Miltenyi Biotec today announced a memorandum of understanding to establish a CAR T manufacturing plant in Hefei, based on the CliniMACS Prodigy and MACSQuant platform。 Miltenyi Biotec’s global leadership in cell processing and related technologies in cell therapy will support PersonGen’s leading CAR T cell pipeline。The collaboration seeks to deepen the supply relationship, develop custom reagents, and explore immunotherapy R&D projects including lentiviral vector development。


Lin Yang, Chairman and CEO of PersonGen-Anke,said: “ It is exciting to intensify our relationship with Miltenyi Biotec,which clearly will enhance our technical capabilities with the world’s first fully automated manufacturing platform. The Prodigy and MACSQuant platforms with Miltenyi Biotec’s training and service approach will meet the aggressive timelines of our clinical CAR T cell projects。”


Boris Stoffel,General Manager at Miltenyi Biotec,said: “For nearly three decades, we have been developing and providing cell therapy solutions for patients worldwide. Exploring the collaboration with PersonGen-Anke has the potential to accelerate the development of new therapy options and give Chinese patients access to future cell and gene therapy products 。”


About cell and gene therapies


Cell and gene therapies are potentially powerful disease modifying treatments that make use of the mechanism of the natural immune system and the currently available genetic information about disease development , specifically cancer. The basic principle is to reprogram the immune cells of patients to be better prepared to fight diseases that evade the typical immune response 。


To make cell and gene therapy treatments, selected populations of cells are taken from a blood sample of the patients and modified to produce the desired therapeutic effect. This can mean replacing a faulty gene in a stem cell or changing receptors in immune cells so they can recognize tumors 。The altered cells are then re-introduced into a patient’s body where they exert their effect by substituting the cells with the faulty genes or educating the immune system to recognize and kill cancer cells 。


PersonGen×Anke Cellular Therapeutics Co., Ltd. is a joint venture company formed by PersonGen BioTherapeutics (Suzhou) Co., Ltd. and Anhui Anke Biotechnology (Group) Co., Ltd. (Stock code: 300009).。PersonGen means Personalized Gene Therapy, implying the dedication to personalized gene therapy, and is committed to achieve one of the most ambitious goals of 21st century medicine: curing cancer. PersonGen is becoming a key player of next generation immuno-oncology in China,especially in the area of CAR-T and CAR-NK cell therapies. For more information,visit www.ankebio.com or www.persongen.com 。


Miltenyi Biotec globally offers products and services that advance biomedical research and cellular therapy 。Our innovative tools support research at every level,from basic research to translational research to clinical application.。This integrated portfolio enables scientists and clinicians to obtain,analyze,and utilize the cell. Our technologies cover techniques of sample preparation, cell isolation, cell sorting,flow cytometry, cell culture,and preclinical imaging 。Our more than 25 years of expertise spans research areas including immunology,stem cell biology, neuroscience,and cancer,and clinical research areas like hematology, graft engineering, and apheresis。In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training。Today, Miltenyi Biotec has more than 2,000 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health 。 Today, our products have been used in more than 50,000 cell therapy procedures 。 For more information please visit www.miltenyibiotec.com 。


PersonGen-Anke Media Contact

Shirley Zhang

+86 55165728067

Shirley.zhang@persongen.com

info@persongen.com


Miltenyi Biotec Media Contact

Svea Lübcke 

Marketing Communications 

Tel.: +49 2204 8306 6683

sveal@miltenyibiotec.de

press@miltenyibiotec.de 

上一篇:众志成城,迎难而上 mg线上娱乐4371诊断试剂事业部举办2017年度工作会议
下一篇:双休日里 mg线上娱乐平台网站保安铲雪忙
XML 地图 | Sitemap 地图